RT Journal Article
SR Electronic
T1 Determinants of HIV infection among pregnant women in Cameroon: A contribution toward the elimination of vertical transmission in low- and middle-income countries
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.15.24307434
DO 10.1101/2024.05.15.24307434
A1 Ndié, Justin
A1 Awono Noah, Jean Pierre Yves
A1 Ateba Ndongo, Francis
A1 Fokam, Joseph
A1 Ketchaji, Alice
A1 Kana Dongmo, Rogacien
A1 Bayiha, Christian Noël
A1 Tchapda, Richard
A1 Palisson, Tatiana Avang Nkoa
A1 Bonyohe, Martial Gaël
A1 Teh Monteh, Caroline
A1 Wepnyu, Njamsnhi Yembe
A1 Naah Tabala, Félicité
A1 Lélé Siaka, Hernandez
A1 Djofang Yepndo, Carelle
A1 Djomo Nzaddi, Audrey Raïssa
A1 Mbella, Maurice Rocher
A1 Dongmo, Marie Micheline
A1 Nguemkam, Gildas
A1 Issouck, Ngo
A1 Monkam, Nelly
A1 Madjo Oumbe, Leopoldine
A1 Moluh, Clifford
A1 Tjek, Paul
A1 Colizzi, Vittorio
A1 Perno, Carlo-Federico
A1 Cappelli, Giulia
A1 Ndembi, Nicaise
A1 Kob, David
A1 Ekane, Gregory-Edie Halle
A1 Keugoung, Basile
A1 Ndjolo, Alexis
A1 Billong, Serge Clotaire
A1 Nkenfou, Céline
A1 Ateudjieu, Jérôme
A1 Zoung-Kanyi Bissek, Anne Cécile
YR 2024
UL http://medrxiv.org/content/early/2024/05/16/2024.05.15.24307434.abstract
AB Background The risk of HIV transmission during antenatal care (ANC) in Cameroon remains a concern. According to recent studies, the prevalence of HIV in the country is around 4.5%, which increases the likelihood of vertical transmission.Objective To identify the determinants of HIV infection among pregnant women attending antenatal clinics (ANC) in Cameroon and to estimate HIV seroprevalence.Methods A cross-sectional study was conducted among ANC attendees aged ≥15 years from September 2022 to June 2023 in 324 health facilities in 08 regions of Cameroon (Adamaoua, Yaounde, East, Far-North, Douala, North, West, South). Sociodemographic and clinical data were collected using questionnaire. HIV screening was performed according to the national algorithm. Estimates of HIV seroprevalence and identification of its determinants using multivariable logistic regression (95% CI) were performed with Excel and SPSS 22 software.Results Overall, 10674 pregnant women were enrolled, with median [IQR] age 25 years [21– 30]; 40.0% at a secondary educational level; 44.1% married monogamously; 46.3% multiparous; 38.8% in the second quarter of pregnancy and 16.5% reporting at least one abortion. Overall HIV seroprevalence was 2.6% [95%CI: 2.33; 2.93]. Significantly higher prevalence was found with the regions of Adamaoua (aOR 3.78 [95%CI: 1.87-7.67], p<0.001), East (9.38 [5.6-15.67], p<0.001), North (3.07 [1.74-5.42], p<0.001), South (2.93 [1.66-5.16]; p<0.001); lack of education (2.08 [1.06-4.06], p=0.032), primary education (2.44 [1.32-4.50], p=0.004) and secondary education (2.29 [1.28-4.08], p=0.005) were significantly associated with HIV infection, while monogamous marriage (0.33 [0.22-0.51], p<0.001), the absence of abortion (0.59 [0.37-0.98], p=0.036) and large multiparous (0.38 [0.17-0.82]; p=0.015) were protective.Conclusion Despite the overall low-prevalence among pregnant women at national-level, several factors are associated with HIV in ANC, the absence or low-level of education, being elderly (>30 years), singleness, history of abortion and low parity predicted the HIV status during ANC. Thus, public health interventions towards these at-risk target groups will help to reduce new infections among pregnant women, hence contributing to achieve eMTCT in Cameroon.Competing Interest StatementThe authors have declared no competing interest.Funding StatementElimination of Mother-to-Child Transmission of HIV ProjectAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the National Ethics Committee for Human Health Research (reference number N°2022/08/1478/CE/CNERSH/SP) and an Administrative Research Authorization (reference number N° 631-26-22) was obtained.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data are available